TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25975871

Group type: EXPERIMENTAL
Intervention: Nova-T380
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Multiload 375
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Copper-T380A
Number of subjects: 120
Study: 24042991

Group type: EXPERIMENTAL
Intervention: Broad compression massage (BCM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Light contact touch (LCT)
Number of subjects: 40
Study: 21640056

Group type: EXPERIMENTAL
Intervention: Active conservative treatment (pelvic floor muscle training - PFMT) delivered by a specialist continence physiotherapist or nurse
Number of subjects: 853

Group type: COMPARATOR
Intervention: Standard management (control group)
Number of subjects: 853

Group type: EXPERIMENTAL
Intervention: Active conservative treatment (PFMT)
Number of subjects: 853
Study: 19537306

Group type: EXPERIMENTAL
Intervention: Margarine fortified with 200 microg folic acid/10 g portion (centre M)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Increasing the consumption of vegetables to three servings per day (centre V)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group (centre C)
Number of subjects: 126
Study: 16280233

Group type: EXPERIMENTAL
Intervention: Detailed verbal instructions and written text about postoperative course
Number of subjects: 92

Group type: COMPARATOR
Intervention: Written text with basic oral explanations (Control)
Number of subjects: 92
Study: 14756716

Group type: EXPERIMENTAL
Intervention: Bupropion SR (150 mg) + lower intensity counseling
Number of subjects: 1524

Group type: EXPERIMENTAL
Intervention: Bupropion SR (150 mg) + higher intensity counseling
Number of subjects: 1524

Group type: EXPERIMENTAL
Intervention: Bupropion SR (300 mg) + lower intensity counseling
Number of subjects: 1524

Group type: EXPERIMENTAL
Intervention: Bupropion SR (300 mg) + higher intensity counseling
Number of subjects: 1524
Study: 11425939

Group type: EXPERIMENTAL
Intervention: Deprenyl treatment
Number of subjects: 800

Group type: COMPARATOR
Intervention: Tocopherol treatment
Number of subjects: 800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800

Group type: COMPARATOR
Intervention: Combination of deprenyl and tocopherol
Number of subjects: 800
Study: 9262882

Group type: EXPERIMENTAL
Intervention: 0.33 mg/kg PPA
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.66 mg/kg PPA
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1 mg/kg PSE
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 2 mg/kg PSE
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8334179

Group type: EXPERIMENTAL
Intervention: 1.8 g protein/kg/day (high N diet)
Number of subjects: 15

Group type: COMPARATOR
Intervention: 1.2 g protein/kg/day (low N diet)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Previous pilot study with 20 similar patients
Number of subjects: 15
Study: 3549902

Group type: EXPERIMENTAL
Intervention: Immunized donor and recipient pretransplant with tetanus toxoid (TT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: T cell-depleted marrow transplantation
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Vaccination with TT at 3, 6, and 12 months posttransplant
Number of subjects: 28

Group type: COMPARATOR
Intervention: Non-immunized donor and/or recipient pretransplant
Number of subjects: 28
Study: 29992824

Group type: EXPERIMENTAL
Intervention: Information technology-based 2-way referral
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (9 community health centers)
Number of subjects: 0
Study: 26909844

Group type: EXPERIMENTAL
Intervention: Real tDCS
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 27
Study: 24607755

Group type: EXPERIMENTAL
Intervention: Induction of labor (IOL) at 41 weeks' gestation and beyond
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Induction of labor (IOL) at 40 weeks' gestation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Induction of labor (IOL) at <40 weeks' gestation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spontaneous labor at <40 weeks' gestation
Number of subjects: 0
Study: 23539236

Group type: EXPERIMENTAL
Intervention: Dexamethasone (14 mg tapered over 3 days)
Number of subjects: 381

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Intensive glucose control (80-110 mg dl(‐1))
Number of subjects: 381

Group type: COMPARATOR
Intervention: Conventional glucose control (180-200 mg dl(‐1))
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Lighter anaesthesia (bispectral index target of 55)
Number of subjects: 381

Group type: COMPARATOR
Intervention: Deeper anaesthesia (bispectral index target of 35)
Number of subjects: 381
Study: 20337844

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (diet and exercise)
Number of subjects: 4864

Group type: EXPERIMENTAL
Intervention: Weight loss diets (low fat, high protein, Mediterranean)
Number of subjects: 4864

Group type: EXPERIMENTAL
Intervention: Regular exercise
Number of subjects: 4864
Study: 17904917

Group type: EXPERIMENTAL
Intervention: Patient preference depression treatment
Number of subjects: 200
Study: 16966541

Group type: EXPERIMENTAL
Intervention: Occurrence of relapses in the first 4 months on study
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Validation dataset (n = 320)
Number of subjects: 256
Study: 12960555

Group type: EXPERIMENTAL
Intervention: Inhaled morphine (3 inhalations [6.6 mg])
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Intravenous morphine (4 mg)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Inhaled morphine (1 inhalation [2.2 mg])
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 10583449

Group type: EXPERIMENTAL
Intervention: Remikiren (600 mg day‐1) single dose
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Remikiren (600 mg day‐1) multiple doses (8 days)
Number of subjects: 25
Study: 8727627

Group type: EXPERIMENTAL
Intervention: Soft cervical collar
Number of subjects: 250

Group type: COMPARATOR
Intervention: No collar (control)
Number of subjects: 250
Study: 2021138

Group type: EXPERIMENTAL
Intervention: Supervised 1‐y walking program
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Increased dietary calcium (milk supplement, 831 mg/d)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo drink (41 mg/d)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sedentary women
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Neither exercise nor dietary calcium
Number of subjects: 36
Study: 6982807

Group type: EXPERIMENTAL
Intervention: Synthetic secretin (Hoe 0690)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 71
Study: 29564720

Group type: EXPERIMENTAL
Intervention: Accordion suturing technique
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-accordion (standard) suturing technique
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 27317302

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 138

Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 25409911

Group type: EXPERIMENTAL
Intervention: Chat-based consultations
Number of subjects: 290

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 290
Study: 23016532

Group type: EXPERIMENTAL
Intervention: Skincare regimen containing retinol, adenosine, and hyaluronic acid applied for 2 months after botulinum toxin A injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Skincare regimen
Number of subjects: 0
Study: 19909752

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a 180 microg/wk plus ribavirin 1000/1200 mg/day for 48 weeks (group A)
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a 180 microg/wk plus ribavirin 1000/1200 mg/day for 72 weeks (group B)
Number of subjects: 551
Study: 17651539

Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg
Number of subjects: 4741

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4741
Study: 16088179

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC) prior to Pringle maneuver
Number of subjects: 75

Group type: COMPARATOR
Intervention: Pringle maneuver
Number of subjects: 75

Group type: COMPARATOR
Intervention: Surgery without vascular clamping
Number of subjects: 75
Study: 12042561

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 20 mg/kg/d
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 30 mg/kg/d
Number of subjects: 43

Group type: COMPARATOR
Intervention: Amoxicillin 50 mg/kg/d
Number of subjects: 43
Study: 9462389

Group type: EXPERIMENTAL
Intervention: Loop ileostomy
Number of subjects: 76

Group type: COMPARATOR
Intervention: Loop transverse colostomy
Number of subjects: 76
Study: 7630132

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Defined formula enteral diet (ENT)
Number of subjects: 17
Study: 2744311

Group type: EXPERIMENTAL
Intervention: DDD/DVI pacing
Number of subjects: 60

Group type: COMPARATOR
Intervention: VVI pacing
Number of subjects: 60

Group type: COMPARATOR
Intervention: VVI mode
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: DDD/DVI mode
Number of subjects: 60
Study: 1234631

Group type: EXPERIMENTAL
Intervention: Whole abdominal irradiation with additional irradiation to the pelvis
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Chemotherapy with melphalan
Number of subjects: 149

Group type: COMPARATOR
Intervention: Whole abdominal irradiation
Number of subjects: 149
Study: 30570431

Group type: EXPERIMENTAL
Intervention: GalNAc3-conjugated PS-modified 2'-O-methoxyethyl ASOs
Number of subjects: 0
Study: 27277839

Group type: EXPERIMENTAL
Intervention: B-clade Tat immunization (30 μg, intradermally, three times at 4-week intervals)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: B-clade Tat immunization
Number of subjects: 200
Study: 25087673

Group type: COMPARATOR
Intervention: Continuous androgen deprivation
Number of subjects: 1535

Group type: EXPERIMENTAL
Intervention: Intermittent androgen deprivation
Number of subjects: 1535
Study: 22872346

Group type: EXPERIMENTAL
Intervention: Educational actions on oral health (school and home visits)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Educational actions on oral health (school group)
Number of subjects: 80
Study: 20169425

Group type: EXPERIMENTAL
Intervention: Melphalan and prednisone (standard of care)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thalidomide, lenalidomide, and bortezomib (new therapies)
Number of subjects: 0
Study: 18946688

Group type: EXPERIMENTAL
Intervention: ADCON-L (bioresorbable carbohydrate polymer gel)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group (no ADCON-L)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Both groups (ADCON-L and Control)
Number of subjects: 119
Study: 15567452

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin, 250 units/kg (n=15)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Enoxaparin, 1 mg/kg (n=16)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Dalteparin, 200 units/kg (n=15)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Tinzaparin, 175 units/kg (n=15)
Number of subjects: 61
Study: 12812387

Group type: EXPERIMENTAL
Intervention: Vital signs measured every 6 hours
Number of subjects: 149

Group type: COMPARATOR
Intervention: Vital signs measured every 8 hours
Number of subjects: 149
Study: 9524046

Group type: EXPERIMENTAL
Intervention: Clonidine (transdermal patch 2.5 mg/week)
Number of subjects: 20
Study: 1365486

Group type: EXPERIMENTAL
Intervention: Droxicam
Number of subjects: 20

Group type: COMPARATOR
Intervention: Piroxicam
Number of subjects: 20
Study: 6351669

Group type: EXPERIMENTAL
Intervention: 10 mg glucose-free bupivacaine (0.5% or 0.75%)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 15 mg glucose-free bupivacaine (0.5% or 0.75%)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 20 mg glucose-free bupivacaine (0.5% or 0.75%)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Various volumes and concentrations of bupivacaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bupivacaine (various doses)
Number of subjects: 60
Study: 31815260

Group type: EXPERIMENTAL
Intervention: Low-dose L. casei (1 bottle per day, n = 142)
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: High-dose L. casei (2 bottles per day, n = 143)
Number of subjects: 429

Group type: COMPARATOR
Intervention: Control group (no intervention, n = 144)
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Low-dose L. casei
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: High-dose L. casei
Number of subjects: 429

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 429
Study: 30825384

Group type: EXPERIMENTAL
Intervention: Systemic amoxicillin 500 mg/metronidazole 400 mg (3×/day, 7 days, n = 170)
Number of subjects: 345

Group type: COMPARATOR
Intervention: Placebo (n = 175)
Number of subjects: 345
Study: 29476990

Group type: EXPERIMENTAL
Intervention: Oral TXA (3 doses of 2 g oral TXA postoperatively)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Intravenous TXA (3 doses of 1 g intravenous TXA postoperatively)
Number of subjects: 108
Study: 27139422

Group type: EXPERIMENTAL
Intervention: DHA supplementation (1.16 g DHA/day for 8 weeks)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (non-enriched beverage)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: DHA supplementation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Temperature (39.5 °C)
Number of subjects: 15
Study: 25179968

Group type: EXPERIMENTAL
Intervention: HeartMate II or HeartWare LVAD
Number of subjects: 126
Study: 22094353

Group type: EXPERIMENTAL
Intervention: Atorvastatin (AT, n=17)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Hormone therapy (HT, n=34)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Hormone therapy plus atorvastatin (HT+AT, n=36)
Number of subjects: 87
Study: 21290833

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Medication (Diclofenac Sodium)
Number of subjects: 60
Study: 17704022

Group type: EXPERIMENTAL
Intervention: 100 mg/d gamma-tocopherol
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 200 mg/d gamma-tocopherol
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 39
Study: 15568206

Group type: EXPERIMENTAL
Intervention: Caffeine (2 mg/kg)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 11837380

Group type: EXPERIMENTAL
Intervention: 500 mg ASA (oral)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 500 mg D,L‐lysine‐mono‐acetylsalicylate (Lys‐ASA) (oral and intravenous)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 1,000 mg Lys‐ASA (oral)
Number of subjects: 13
Study: 9428456

Group type: EXPERIMENTAL
Intervention: Total-dose intravenous iron dextran infusion
Number of subjects: 43

Group type: COMPARATOR
Intervention: 500-mg infusion to total dose
Number of subjects: 43

Group type: COMPARATOR
Intervention: 100-mg bolus to total dose
Number of subjects: 43
Study: 8562292

Group type: EXPERIMENTAL
Intervention: Aspirin 1000 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Codeine 60 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 0
Study: 2200632

Group type: EXPERIMENTAL
Intervention: Iopromide (50 or 100 ml, 370 mgI/ml)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Iopamidol (50 or 100 ml, 370 mgI/ml)
Number of subjects: 0
Study: 7387335

Group type: EXPERIMENTAL
Intervention: 20 mg beta-endorphin intravenous injection
Number of subjects: 9

Group type: COMPARATOR
Intervention: 10 mg morphine sulfate
Number of subjects: 9
Study: 30946445

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 0
Study: 27810904

Group type: EXPERIMENTAL
Intervention: Motolimod (VTX-2337) at 3.0 mg/m2 combined with cetuximab
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Motolimod (VTX-2337) at 3.5 mg/m2 combined with cetuximab
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Motolimod (VTX-2337)
Number of subjects: 13
Study: 26982794

Group type: EXPERIMENTAL
Intervention: Clobetasol 0.05%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vehicle (petrolatum or lacquer)
Number of subjects: 40
Study: 24114437

Group type: EXPERIMENTAL
Intervention: Precision training (stepping over obstacles and onto targets on the ground)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endurance training (treadmill training with body weight support, if needed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10-Meter Walk Test (10MWT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Six-Minute Walk Test (6MWT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SCI-FAP
Number of subjects: 0
Study: 25191546

Group type: EXPERIMENTAL
Intervention: High ALA and sn-1,3-DAG
Number of subjects: 23

Group type: COMPARATOR
Intervention: High ALA and TAG
Number of subjects: 23
Study: 19875397

Group type: EXPERIMENTAL
Intervention: Segmental pulmonary vein isolation (S‐PVI)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Circumferential pulmonary vein isolation (C‐PVI)
Number of subjects: 101
Study: 17264187

Group type: EXPERIMENTAL
Intervention: Sibutramine (10 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 14572304

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Rescue medication (oxygen, dexamethasone, acetazolamide)
Number of subjects: 47
Study: 11269488

Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (LVRS) plus medical therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 0
Study: 9680346

Group type: EXPERIMENTAL
Intervention: MACOP-B (methotrexate with leucovorin, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine)
Number of subjects: 40
Study: 8044606

Group type: EXPERIMENTAL
Intervention: Laser photocoagulation
Number of subjects: 44

Group type: COMPARATOR
Intervention: Adrenaline injection (1:10,000)
Number of subjects: 44
Study: 2141488

Group type: EXPERIMENTAL
Intervention: Diethyl stilboestrol (DES) 3 mg/day
Number of subjects: 250

Group type: COMPARATOR
Intervention: Goserelin 3.6 mg/month
Number of subjects: 250
Study: 271171

Group type: EXPERIMENTAL
Intervention: Vigorous treatment (CAT)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Mild induction program (VAMP)
Number of subjects: 101
Study: 31850687

Group type: EXPERIMENTAL
Intervention: Maintenance capecitabine + bevacizumab (CAP-B)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 450
Study: 31492102

Group type: EXPERIMENTAL
Intervention: recombinant human thrombopoietin (rhTPO)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (standard treatment based on Surviving Sepsis Campaign guidelines)
Number of subjects: 200
Study: 27649469

Group type: EXPERIMENTAL
Intervention: Pictures of natural vulvas
Number of subjects: 43

Group type: COMPARATOR
Intervention: Pictures of neutral objects
Number of subjects: 43
Study: 26278623

Group type: EXPERIMENTAL
Intervention: Telephone-based CBT
Number of subjects: 397

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 397
Study: 23925361

Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg/kg every 4 weeks
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study: 21324133

Group type: EXPERIMENTAL
Intervention: Directly Administered Antiretroviral Therapy (DAART) for 12 months
Number of subjects: 107

Group type: COMPARATOR
Intervention: Self-Administered Therapy (SAT)
Number of subjects: 107
Study: 19359420

Group type: EXPERIMENTAL
Intervention: SCI patients
Number of subjects: 12

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 12
Study: 17061611

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (2000 mg per day for 20 days)
Number of subjects: 414

Group type: COMPARATOR
Intervention: Baseline serum calcium and alkaline phosphatase levels
Number of subjects: 414
Study: 14734700

Group type: EXPERIMENTAL
Intervention: Reduction group (102 smokers)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Waitlist group (49 smokers)
Number of subjects: 153
Study: 11553186

Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 16

Group type: COMPARATOR
Intervention: Soluble human insulin
Number of subjects: 16
Study: 9713447

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 1600 micrograms per day
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 7871359

Group type: EXPERIMENTAL
Intervention: Cultivation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Evalusite (ELISA kit)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: OmniGene (DNA probes)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Indirect immunofluorescence (IIF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Commercial systems
Number of subjects: 20
Study: 2493897

Group type: EXPERIMENTAL
Intervention: Captopril (two 25 mg doses in 24 hours)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (two tablets in 24 hours)
Number of subjects: 64
Study: 4931824

Group type: EXPERIMENTAL
Intervention: LB 46 (prinodolol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0
Study: 31789981

Group type: EXPERIMENTAL
Intervention: Intravascular cooling
Number of subjects: 934

Group type: COMPARATOR
Intervention: Surface cooling
Number of subjects: 934
Study: 31264510

Group type: COMPARATOR
Intervention: PF-06412562 45 mg
Number of subjects: 95

Group type: COMPARATOR
Intervention: PF-06412562 (3 mg, 9 mg, 45 mg)
Number of subjects: 95
Study: 28364099

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1.0 μg/kg loading dose for 10 min followed by 0.5 μg/(kg.h) during OLV)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control (0.9% saline)
Number of subjects: 56
Study: 25645599

Group type: EXPERIMENTAL
Intervention: Massage therapy (15 minutes daily)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control
Number of subjects: 161